Acutis Summer Webinar, July 18, 2019

Our Summer Webinar was led by Dr. Daniela Zaborskis and featuring Senior Researcher, Mumtaz Akhtar, has provided a review and expert opinion in a discussion on the pharmacological, medical and social implications of designer drugs: synthetic cannabinoids and fentanyl analogs.

The prevalence of these substances constitutes a crisis, which compels us to hone our understanding of these substances, and to better deliver the most effective diagnoses and care. 

The seminar offers:

  • A summary of two types of designer drugs:
    fentanyl analogs and synthetic cannabinoids

  • A review of the basic pharmacology
    of these dangerous and illicit substances 

  • A discussion of the seemingly innumerable varieties
    of drugs being abused

These and other relevant areas of interest will be illustrated
with case studies and which will provide participants with important “take-home” points. In addition to having the opportunity to participate in an important and focused discussion, those who attend will earn continuing medical education credits.

daniela-1.jpg

Moderator

Daniela Zaborskis
PhD, Director of Operations and Senior Scientist

Mumtaz3.jpg

Featuring

Mumtaz Akhtar
Acutis’ Senior Researcher

Colleagues, peers and participants can download
the contents of our synthetic cannabinoids and fentanyl analogs webinar below.

 
trait.jpg
 

Acutis Winter Webinar, March 21, 2019

Our Winter Webinar was led by Dr. Jeffrey Fudin
and featured Daniela Zaborskis, PhD., Director of Operations and Senior Scientist, Acutis Diagnostics.

Dr. Fudin has long been recognized as an indispensable resource for medical, pharmacological, pain and substance-abuse specialists.

Fudin_Albany-080117_2T8B3483_C-2.jpg

As an expert in pain management and pharmacotherapy, Dr. Fudin prepared a set of objectives for the day that included: 

- A summary of the neurobiology of opioid addiction 

- A review of basic pharmacology as it applies to opioids 

- A discussion of the pharmacology and pharmacokinetics of buprenorphine 

These and other relevant areas of interest were illustrated with case studies and specific “take-home” points. In addition to having the opportunity to participate in an important and focused discussion, participants earned continuing medical education credits. 

Colleagues, peers and participants can download
the contents of our buprenorphine pharmacology and opioid neurobiology webinar below.

 

Acutis Webinars

 
icone-webinar.jpg

The advantage of a webinar lies in its interactivity. In a webinar, you are both a member of the audience and, if you choose, a participant, where you’ll have the opportunity to share your ideas and ask questions to deepen your understanding of the topic.

We plan to offer regular opportunities for you to participate in events where the most important issues in our industry are addressed by leaders in the field.

Acutis Webinars offer 1 continuing education credit 

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Annenberg Center for Health Sciences at Eisenhower and Acutis Diagnostics, Inc. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians. 

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207. This program is accredited for 1.0 contact hour. 

The Annenberg Center maintains responsibility for this program and its content. This activity is designated by the Annenberg Center for 1.0 hour of credit. 

 
aanp.jpg
 
 

Acutis Symposia

 
icone-symposia (1).jpg


Acutis Symposia
are professional and social events that truly matter.

Each symposium, led by a distinguished speaker, will provide clients, colleagues and others with the opportunity to meet and discuss the most critical issues facing the industry today.

Acutis’ first Autumn Symposium:
“You’re in control or urine control:
clinical pearls of drug-testing case studies.”

On October 23, 2018, Acutis held its first Autumn Symposium, a dinner featuring Dr. Jeffrey Fudin, Pharm.D., the renowned clinical pharmacy specialist, opioid risk management specialist. Dr. Fudin spoke on topics related to treatment of substance abuse & addiction, emphasizing Urine Drug Monitoring (UDM), to an audience of almost 20 physicians, clinicians and pharmacists.

Dr. Fudin’s talk “You’re in control or urine control: clinical pearls of drug testing case studies” established 3 Learning Objectives including:

1. Differentiating between in-office qualitative testing
and laboratory quantitative testing

2. Four case studies:
a. Sample validity
b. Table scrapping
c. THC elimination
d. “I swear it’s not cocaine … it’s lidocaine!

3. Street trends, focusing on synthetics and naturally-derived illicit substances.

Fudin_Albany-080117_2T8B3483_C-2.jpg

featuring

Dr. Jeffrey Fudin, Pharm. D.
Clinical pharmacy specialist,
opioid risk management

Dr. Fudin offered ways for physicians and others to better understand the science and mechanics of monitoring, including differentiating between in-office qualitative and laboratory quantitative testing. He further explained how this information could be used to improve clinical assessment and patient care. Fudin also addressed topics ranging from the comparative street value of pharmaceutical drugs and the complex nature of regulations, to the surprisingly sophisticated marketing practices of drug dealers, in particular, their use of clever street names of illegal substances.

The thrust of his talk was the proper use of UDM and its rationale to help ensure compliance, while both mitigating risk and justifying issuing prescriptions. He provided reasons for testing to achieve better outcomes, from the monitoring of patients to support for behavior modification, including referral to psychologists. The case studies he provided were likely familiar to those in attendance, but were presented in a sufficiently detailed manner to provide real insights. At the end of his talk, attendees were encouraged to ask questions and to share their own experiences.

The event, which took place at Longfellows, Saratoga Springs, NY, Hotel, Restaurant, and Conference Center, was as professional as it was collegial. Future Acutis Symposia will feature the industry’s most dedicated and successful professionals working to address the most challenging health issues we face today.